AI-extracted from the 10-Q filed 2026-08-04 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
IDEAYA recognized $8.9M collaboration revenue from Servier darovasertib license deal in Q2, with net loss of $112.5M as R&D spending surged 41% YoY on clinical trial expansion.
Biggest Revenue Drivers
Collaboration revenue$8.9Mnew in Q2 2026
Recognition of development and commercialization license and R&D services from Servier License Agreement executed August 2025 for darovasertib outside US.
Biggest Revenue Drivers
Total revenue: $8.9Mfrom $0M in Q2 2025
Collaboration revenue$8.9Mnew in Q2 2026
Recognition of development and commercialization license and R&D services from Servier License Agreement executed August 2025 for darovasertib outside US.
Largest Expense Items
Research and development$108.7M+46% YoY
Increased CRO and CMO fees for clinical trial advancement, personnel costs, and milestone payments across darovasertib and other product candidates.
Margins: The company generated positive collaboration revenue for the first time but remains deeply unprofitable. Operating loss of $122.3M was partially offset by $9.8M interest income, resulting in net loss of $112.5M. No gross margin applicable; pre-revenue development-stage company.
Watch Items from the Filing
Accumulated deficit of $947.5M as of June 30, 2026; company expects continued substantial losses and requires additional capital raises. Management states $1.24B cash sufficient for 'at least twelve months' of operations.
Lead program darovasertib (PKC inhibitor) reported positive Phase 2/3 data in mUM (OptimUM-02) in April 2026, targeting NDA submission H2 2026. Pfizer provides crizotinib at no cost for combination studies.
Recent license agreements with Hengrui Pharma (IDE849 DLL3 ADC, $1.045B milestones) and Biocytogen (IDE034, $395M milestones) committed in H2 2024–H1 2026; total remaining milestone obligations exceed $1.5B across programs.
External clinical development spending Q2 2026: darovasertib $32.1M, IDE849 $7.4M, IDE034 $3.2M, IDE892 $4.0M, IDE574 $3.2M, IDE161 $2.0M, IDE397 $2.9M. Portfolio expansion with six active programs.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Yarno Wendy LReporting ownerGrant or award · Jun 16, 2026
Snyder Douglas B.SVP, General CounselGrant or award · Jan 30, 2026
Dorman StuartChief Commercial OfficerGrant or award · Jan 30, 2026
About IDEAYA Biosciences, Inc. (IDYA): stock profile, AI score and financials
IDEAYA Biosciences, Inc. (IDYA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IDYA at 36.2/100 on a composite quality score built from its SEC filings, placing it at rank #2,265 of 2,925 stocks — the bottom half of the AI-ranked universe. IDYA scores in the top quartile across revenue growth (98.3). Areas of concern include profitability (8.9) and free cash flow (9.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), IDEAYA Biosciences, Inc. reports quarterly revenue of $8.9M, net income of $-112.5M, free cash flow of $-89.1M. Top institutional holders of IDYA by reported 13-F value include FMR, BlackRock, Jupiter Topco, based on the most recent SEC filings. IDYA trades on the Nasdaq exchange and files with the SEC under CIK 1676725. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IDYA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IDEAYA Biosciences, Inc. directly from SEC EDGAR.